In June 2016, a review of "Am J Kidney Dis" addressed the debate over the management of blood fat in patients with chronic Kidney disease and the reduction in cardiovascular risk in statins.
Adult chronic kidney disease (CKD) has a higher risk of death from cardiovascular disease. Statins vs placebo randomized clinical trial results show that the statin drugs or statin + according to fold the mab can reduce the dialysis dependence of adult patients with chronic kidney disease (CKD) the absolute risk of coronary heart disease and death. Of the 2013 clinical practice guidelines to improve the global kidney disease outcome, in lipid management section, recommended over 50 non dialysis dependence statin use for patients with chronic kidney disease (CKD) or treatment, joint according to fold the mab has nothing to do with the low density lipoprotein cholesterol levels. But, in the past five years, at least nine published guidelines for lipid management for atherosclerosis primary prevention and secondary prevention of cardiovascular disease, and not all guide pointed out that the effectiveness of lipid-lowering therapy in adult patients with chronic kidney disease (CKD). Most accept most of the clinical treatment for patients with chronic kidney disease (CKD) from the nephrologist, used for the prevention of cardiovascular diseases lipid-lowering treatment recommended differences may the clinical care of adult patients with chronic kidney disease (CKD) adverse effects, and can lead to chaos in the patients and medical staff. This review summarizes the identification and management of blood lipid levels in patients with CKD, and discusses the debate on the detection and treatment of blood lipid levels in people with CKD.